Search
Discover the power of prenatal screening on B·R·A·H·M·S KRYPTOR for your laboratory
Our Thermo Scientific B·R·A·H·M·S Biomarkers offer a wide range of options to cover screening strategies throughout pregnancy. With our solution, you have the flexibility to choose the most suitable biomarkers for your specific screening needs. By utilizing just one instrument, you can streamline your workflow and optimize efficiency in your laboratory.
| First trimester | Second/third trimester |
| B·R·A·H·M·S PAPP-A KRYPTOR | B·R·A·H·M·S PlGF plus KRYPTOR |
| B·R·A·H·M·S PlGF plus KRYPTOR | B·R·A·H·M·S sFlt-1 KRYPTOR |
All the intended uses covered by our assays have been clinically validated ensuring the highest clinical performance and are fully compliant with the IVDR.
| T1 | T2 | T3 | Cut-off | |
| Screening | PIGF PAPP-A |
PlGF / sFlt-1, from week 19 / 19–24 weeks |
PIGF sFlt-1 |
It is the responsibility of the user to choose the cut-off which will apply for further procedures |
| Aid for diagnosis | sFlt-1/PlGF, from week 20 |
sFlt-1/PIGF | 85 | |
| Short-term prediction | sFlt-1/PlGF, from week 20 |
sFlt-1/PIGF | 66 |
Optimize your laboratory routine with prenatal screening on B·R·A·H·M·S KRYPTOR for pre-eclampsia management
Powered by Nobel Prize-winning TRACE technology, B·R·A·H·M·S KRYPTOR analyzers, and biotin-free assays, are designed to help ensure robust performance and consistent precise results, minimizing the impact of potential interferences. These user-friendly bench-top instruments are easily integrated into any laboratory. Enhance prenatal screening in your lab with:
- A full portfolio on B·R·A·H·M·S KRYPTOR GOLD Analyzer to consolidate your prenatal screening on one instrument only
- An easy and straightforward laboratory routine requiring less operator intervention
- With the self-determining dilution factor, eliminate cumbersome re-run of out-of-range samples and improve turnaround time for your patients allowing the use of B·R·A·H·M·S KRYPTOR in your OSCAR* clinic
- Cost reduction due to efficient sample processing
- Low level of liquid and plastic waste for an environment friendly solution
* One Stop Clinical Assessment of Risk
Experience high levels of precision in your lab
Trust our solution for superior accuracy and consistency, with high confidence and optimal CV widely used over 20 years to support your
clinical practice
UK NEQAS Quality Data B·R·A·H·M·S™ PAPP-A KRYPTOR⁵
UK NEQAS Quality Data B·R·A·H·M·S Free βhCG KRYPTOR⁵
Benefits of B·R·A·H·M·S KRYPTOR assays:
- Enhanced efficiency in lot validation
- Stable medians with minimal updates needed
- Reliable results for improved clinical decisions
Prioritize quality for your patients to support your clinical practice
In a published multicenter study (Jones et al., 2023), samples previously measured with alternative PAPP-A assays generated
falsely elevated risk estimates, with values suggestive of analytical interference. Reanalysis on the B·R·A·H·M·S KRYPTOR platform confirmed the presence of this interference, with the platform clearly identifying it and providing results consistent with the clinical outcomes observed in those pregnancies.
Verification of abnormally low PAPP-A results with an alternative method such as B·R·A·H·M·S KRYPTOR
analyzer would have helped exclude assay interference and prevent false-positive risk assessments.
Easy interpretation with the single cut-off for sFlt-1/PlGF ratio
With the sFlt-1/PlGF ratio on B·R·A·H·M·S KRYPTOR, you can offer support for pre-eclampsia diagnosis and short-term prognosis to your clinicians.
With the universal cut-off of 66, clinical use of the sFlt-1/PlGF on B·R·A·H·M·S KRYPTOR for short-term prognosis and diagnosis of pre-eclampsia is easy and safe. The sFlt-1/PlGF ratio at cut-off 66 on B·R·A·H·M·S KRYPTOR has a clinical sensitivity of 82% and a clinical specificity of 91%, as described below.³
.jpg "Image illustrating cut-off 66 for the sFl1-1/PlGF ratio. Evidence shows optimal predictive performance with a KRYPTOR-specific cut-off at 66 for the sFlt-1/PlGF ratio. With a ratio of less than 66, there is a low risk of developing pre-clampsia and at a ratio greater than or equal to 66, there is a high risk of developing pre-eclampsia.")
Expert perspectives and practical learning in pre-eclampsia
Pre-eclampsia diagnosis with a single cut-off ratio
Enhance your clinical evaluation with a validated sFlt-1/PlGF ratio of 66 for confident short-term prognosis and diagnosis. Download this resource to see how this sinlge threshold helps avoid doubtful results and supports safe, expectant management.
Efficiency & resource management focus
In suspected pre-eclampsia cases, timely and reliable assessment is essential. The sFlt-1/PlGF ratio provides objective support for short-term evaluation, helping stratify patients and optimize care pathways. This approach can improve the efficient use of hospital resources.
From placentation to prophylaxis: a new window into pre-eclampsia
Deepen your understanding of the central role of the placenta and the antiangiogenic state that triggers endothelial dysfunction. This article details evidence-based prevention strategies, including optimal ASA prophylaxis, and explains the long-term cardiovascular risks identifying women for structured follow-up care.
Thermo Scientific B·R·A·H·M·S sFlt-1/PlGF KRYPTOR ratio was the first FDA-cleared test supporting the stratification of pregnant women with pre-eclampsia with severe features on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS Analyzer.
Learn from our customers: B∙R∙A∙H∙M∙S KRYPTOR GOLD for pre-eclampsia screening
Additional resources
References
- Wright D et al. Ultrasound Obstet Gynecol 2010; 36: 404-411
- Jones et al. Ultrasound Obstet Gynecol 2023; 61(6) :776-777
- Andersen LLT et al. J Am Heart Assoc. 2021;10(17):e021376
- Thadhani et al. (2022). NEJM 2022 :1(12)
- UK NEQAS results from february 2003 – december 2024
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.
B·R·A·H·M·S KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.